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Abstract
Background: Recent research shows that the prevalence of patients with very severe chronic obstructive pulmonary
disease (COPD), congestive heart failure (CHF) and chronic renal failure (CRF) continues to rise over the next years.
Scientific studies concerning self-perceived symptoms and care needs in patients with severe to very severe COPD, CHF
and CRF are scarce.
Consequently, it will be difficult to develop an optimal patient-centred palliative care program for patients with end-stage
COPD, CHF or CRF. The present study has been designed to assess the symptoms, care needs, end-of-life care
treatment preferences and communication needs of patients with severe to very severe COPD, CHF or CRF.
Additionally, family distress and care giving burden of relatives of these patients will be assessed.
Methods/design: A cross-sectional comparative and prospective longitudinal study in patients with end-stage COPD,
CHF or CRF has been designed. Patients will be recruited by their treating physician specialist. Patients and their closest
relatives will be visited at baseline and every 4 months after baseline for a period of 12 months. The following outcomes
will be assessed during home visits: self-perceived symptoms and care needs; daily physical functioning; general health
status; end-of-life care treatment preferences; end-of-life care communication and care-giver burden of family caregivers.
Additionally, end-of-life care communication and prognosis of survival will be assessed with the physician primarily
responsible for the management of the chronic organ failure. Finally, if patients decease during the study period, the
baseline preferences with regard to life-sustaining treatments will be compared with the real end-of-life care.
Discussion:  To date, the symptoms, care needs, caregiver burden, end-of-life care treatment preferences and
communication needs of patients with very severe COPD, CHF or CRF remain unknown. The present study will increase
the knowledge about the self-perceived symptoms, care-needs, caregiver burden, end-of-life care treatment preferences
and communication needs from the views of patients, their loved ones and their treating physician. This knowledge is
necessary to optimize palliative care for patients with COPD, CHF or CRF. Here, the design of the present study has
been described. A preliminary analysis of the possible strengths, weaknesses and clinical consequences is outlined.
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Background
Chronic diseases like chronic obstructive pulmonary dis-
ease (COPD), congestive heart failure (CHF) or chronic
renal failure (CRF) are nowadays major causes of morbid-
ity and mortality worldwide.[1] Recent research shows
that the prevalence of patients with very severe COPD [2],
CHF [3] and CRF [4] continues to rise over the next years.
Life prolongation is not the ultimate goal of management
of patients with severe to very severe COPD, CHF or CRF.
Management of these patients should prevent, relieve
and/or soothe self-perceived symptoms and care needs to
optimise daily functioning and stabilize disease-specific
health status. [5-9] The management of patients with
severe to very severe COPD, CHF or CRF should probably
be a holistic type of care, equally concerned with physical,
psychosocial and spiritual aspects of each patient.[10]
To the best of the present authors' knowledge, no manage-
ment/treating program is currently aiming at the self-per-
ceived symptoms and care needs of patients with severe to
very severe COPD, CHF or CRF.
In fact, it is currently unknown whether and to what
extent patients with severe to very severe COPD, CHF or
CRF suffer from self-perceived symptoms before they
enter the last phase of their life and how they develop
throughout the final course of the disease. At present, it is
only known that patients with end-stage COPD, CHF or
CRF have suffered from incapacitating symptoms while
only a minority of these symptoms/problems has been
treated appropriately. [11-16] In the interest of patients
with severe to very severe COPD, CHF or CRF, but also in
the interest of their close relatives, it is of major impor-
tance to extent the currently available knowledge concern-
ing assessment and treatment of self-perceived symptoms
and care needs to optimise existing treatment options, to
develop completely new treatment options and to offer
adequate relief of self-perceived symptoms and care
needs.
It remains very difficult to predict survival in patients with
end-stage chronic organ failure. Indeed, physicians' pre-
dictions of survival in patients with various serious
chronic conditions were often erroneous and optimis-
tic.[17,18] Moreover, a fundamental issue affecting the
prediction of survival of patients with severe to very severe
COPD or CHF is the hypothetical death trajectory: a slow
decline in quality of life punctuated by acute exacerba-
tions of COPD or CHF from which patients with severe to
very severe COPD or CHF will only partially recover until
a final crisis occurs that cannot or will not be treated. [19-
21]
It is therefore of great importance for patients with severe
to very severe COPD, CHF or CRF to get to know and dis-
cuss survival and the preferences and consequences of life-
sustaining interventions (i.e. mechanical ventilation and
cardiac resuscitation) with their family and the treating
physician.[22] In fact, finding out and honouring the
treatment preferences of terminally ill patients is most
probably critical for the provision of high-quality end-of-
life care. Moreover, patients with severe to very severe
COPD, CHF or CRF who want to spend their end-of-life
period as they want, should probably leave better advance
directives. For example, a recent study in patients with
chronic renal failure reported that about one-third of the
close relatives and about one-third of the treating physi-
cians predicted incorrectly the current preferences for car-
diopulmonary resuscitation and haemodialysis under
various circumstances.[23] The contents and quality of
end-of-life communication between patients with severe
to very severe COPD, CHF or CRF, their closest relatives
and their physician remain currently unknown.
Patients with severe to very severe chronic diseases like
COPD, CHF or CRF may experience problems with per-
forming normal daily tasks.[24] When the patient is still
living at home, most of the care needs may be carried out
by family members.[25] This may involve participation in
personal hygiene needs, administration of medication,
attention to nutritional needs, psychological support and
emergency management of problems such as excessive
shortness of breath [26], but also heavy physical work of
transferring a weak patient and attending needs such as
laundering and cleaning. A recent study in 18 patients
with COPD, CHF or CRF suggests that decreased inde-
pendence and social isolation imposes a considerable
burden of care on the family.[10] Additionally, Barnes
and colleagues have shown that carers of CHF patients
have other characteristics than carers of patients with can-
cer and need practical and emotional support.[27] At
present, it remains unknown whether and to what extent
self-perceived symptoms and care needs of patients with
severe to very severe COPD, CHF or CRF may result in an
extra caregiver burden for close relatives. It is therefore
reasonable to hypothesize that for the families and loved
ones of patients with severe to very severe COPD, CHF or
CRF there is also great distress, which may increase while
the symptoms and care needs of patients with severe to
very severe COPD, CHF or CRF progress over time.
Indeed, standing witness of physical [28] and emotional
distress of the patient [29], bearing the burdens of extra
care [25] and future anticipated loss will most probably
cause substantial family distress. By identifying, under-
standing and addressing factors that may potentially over-
come patients with severe to very severe COPD and their
family, the necessary preconditions for coping and man-
aging of will be established.[6]BMC Palliative Care 2008, 7:5 http://www.biomedcentral.com/1472-684X/7/5
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Currently, the change over time in self-perceived symp-
toms, care needs and preferences with regard to life-sus-
taining treatments and communication about end-of-life
care in patients with severe to very severe COPD, CHF or
CRF remain unknown too.
Aims of the study
In the present study we aim to elaborate the currently
available knowledge concerning the self-perceived symp-
toms, care needs, caregiver burden, preferences with
regard to life-sustaining treatments and communication
about end-of-life care in patients with end-stage chronic
organ failure, in particular COPD, CHF or CRF. To achieve
this aim we need to answer the following questions:
1.1 What are the self-perceived symptoms and care needs
of patients with severe to very severe COPD, CHF or CRF
and to what extent do they differ from each other?
1.2 Do these self-perceived symptoms and care needs
relate to patients' daily functioning, health status and
mood status?
1.3 Whether and to what extent are self-perceived symp-
toms and care needs different between patients with
severe COPD, very severe COPD without long-term oxy-
gen therapy or very severe COPD with long-term oxygen
therapy?
2.1 How are the self-perceived symptoms of patients with
severe to very severe COPD, CHF or CRF perceived by
their closest relatives?
2.2 Whether and to what extent do self-perceived symp-
toms and care needs of patients with severe to very severe
COPD, CHF or CRF affect caregiver burden?
3.1 What are the preferences with regard to life-sustaining
treatments of patients with severe to very severe COPD?
3.2 Whether and to what extent do the preferences with
regard to life-sustaining treatments of patients with severe
to very severe COPD differ from those of patients with
end-stage CHF or CRF?
4.1 How do patients with severe to very severe COPD,
CHF or CRF and their closest relatives perceive end-of-life
care planning (i.e. communication about survival progno-
sis and life-sustaining treatments) with the treating physi-
cian?
5.1 How do self-perceived symptoms, care needs, car-
egiver burden, preferences with regard to life-sustaining
treatments, end-of-life care communication and manage-
ment of patients with severe to very severe COPD, CHF
and CRF change over time according to the patients and
their closest relatives?
The objective of this article is to describe the design of the
present study and inform others on the possibilities of
performing end-of-life care research in end-stage chronic
organ failure, especially in COPD, CHF or CRF. In partic-
ular, the prospective and longitudinal study design, in
which the views of patients, their relatives and physician
will be taken into account for the assessment of daily
symptoms, care needs, caregiver burden, end-of-life care
treatment preferences and communication needs in three
groups of patients with end-stage chronic organ failure
has not been described before. The described methodol-
ogy will also serve as detailed reference for the method
section of future publications of this study.
Methods/design
Design
A cross-sectional comparative study in patients with end-
stage COPD, CHF or CRF has been designed to answer
question 1.1 to 4.1. Additionally, a longitudinal follow-
up study has been designed to answer question 5.1.
Patients and their closest relatives will be visited at base-
line and every 4 months after baseline for a period of 12
months. Figure 1
Study population
The study population consists of patients with severe to
very severe COPD, end-stage CHF and end-stage CRF. All
patients will be recruited by their physician specialist (n =
about 25) at the outpatient consultation in one academic
hospital and six general hospitals throughout the south-
ern-eastern part of the Netherlands. Patients and their
closest relatives will be included. Additionally, the partic-
ipating physician specialist primarily responsible for the
management of the chronic organ disease of the enrolled
patients will be included.
Inclusion criteria are: patients with severe COPD (Global
initiative for chronic Obstructive Lung Disease (GOLD)
Study design Figure 1
Study design. Timing of the interviews.
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classification III); patients with end-stage COPD (GOLD
classification IV) without long-term oxygen therapy
(LTOT); patients with end-stage COPD (GOLD classifica-
tion IV) with LTOT; patients with end-stage CHF (New
York Heart Association (NYHA) classification III and IV)
and patients with end-stage CRF (requiring dialysis).
Exclusion criteria are: the patient is not clinically stable for
at least 4 weeks preceding enrolment (no hospital admis-
sion or major change in medication, according to the
treating physician specialist); pharmacological therapy is
not optimal (according to the current available guide-
lines) and stable for at least 2 months preceding enrol-
ment and patients in a nursing home.
The lack of previous results makes it impossible to per-
form power calculations. The intended sample size will be
150 patients with COPD (GOLD classification III, n = 50;
GOLD classification IV without LTOT, n = 50; GOLD clas-
sification IV with LTOT, n = 50); 100 patients with CHF
(NYHA class III, n = 50; NYHA class IV, n = 50) and 100
patients with CRF (haemodialysis, n = 50; peritoneal dial-
ysis, n = 50).
Instruments
After oral and written informed consent has been given by
participating patients, the following outcomes will be
assessed at the patients' home-environment: demograph-
ics; current self-reported comorbidities: Charlson comor-
bidity index [30]; disease history; general health status:
EuroQol-5 Dimensions (EQ-5D) [31], Assessment of
Quality Of Life (AQOL) [32], Medical Outcomes Study
36-Item Short-Form Health Survey (SF-36) [33]; disease-
specific health status: St. Georges Respiratory Question-
naire (SGRQ, only for COPD patients) [34], Minnesota
Living with Heart Failure Questionnaire (MLHFQ, only
for CHF patients) [35], Kidney Disease Quality Of Life
questionnaire (KDQOL, only for CRF patients) [36]; anx-
iety and depression: Hospital Anxiety and Depression
Scale (HADS) [37]; daily physical functioning: Timed 'Up
and Go' test (TUG) [38], Care Dependency Scale (CDS)
[39]; symptom checklist for the patients to determine the
degree of self-perceived physical and psychological symp-
toms using Visual Analogue Scales (VAS); current disease
management checklist; end-of-life care communication:
Quality Of Communication questionnaire (QOC) [40],
Barriers and Facilitators Questionnaire (BFQ) [41]; end-
of-life care treatment preferences [42], Willingness to
Accept Life-sustaining Treatments questionnaire (WALT)
[22]; weight and length (only at baseline). Additionally,
NT-proBNP [43], creatinine and lung function (spirome-
try, Forced Expiratory Volume in the first second (FEV1))
will be measured at baseline to assess previously unrecog-
nised co-existing morbidities.
Patients will be asked to identify the person who spends
most time with them and provides most of their care,
assistance and support.[44] After oral and written
informed consent has been given by participating close
relatives of enrolled patients, the following outcomes will
be assessed at their home-environment: care-giver bur-
den: Family Appraisal of Care giving Questionnaire for
Palliative Care (FACQ-PC) [45]; perception of the
patient's symptoms checklist; barriers and facilitators in
end-of-life care communication: BFQ [41] and general
well being: semi-structured interview. If possible, relatives
will not be interviewed in the presence of the patient.
The participating physician specialist primarily responsi-
ble for the management of the chronic organ disease of
the enrolled patients will be interviewed at baseline to
assess end-of-life care communication and prognosis of
survival of the patient with chronic organ disease.
If patients decease during this period, the first author will
call the relatives to compare the most recent end-of-life
care treatment preferences of the patient with the real end-
of-life care (e.g. place of dying, the use of life-sustaining
treatments like resuscitation or invasive ventilation).
Finally, for patients with COPD or CHF the number of
exacerbations/acute heart decompensation during every
4-month period will be assessed using a diary, which has
to be filled out every day. Complications of dialysis will
be assessed every four months at the dialysis department.
From a group of non-participating patients some data like
severity of disease (GOLD classification or NYHA classifi-
cation), age and gender will be collected.
Questionnaires that were not available in Dutch (AQOL,
QOC, BFQ, WALT and FACQ-PC) have been translated
into Dutch by the procedure of forward-backward transla-
tion.
Ethical considerations
The study will be conducted according to the principles of
the Declaration of Helsinki [46] and in accordance with
the Medical Research Involving Human Subjects Act
(WMO).
The load for patients has been tested in three volunteering
patients with end-stage COPD and two relatives. The load
for patients will be low, because patients will be visited at
home, mainly for filling in questionnaires. This will prob-
ably not increase discomfort and sensations like dyspnea.
All patients will be recruited at the outpatient consulta-
tion of their treating physician in one academic hospital
and six general hospitals. Patients will receive the patientBMC Palliative Care 2008, 7:5 http://www.biomedcentral.com/1472-684X/7/5
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information letter and the informed consent form.
Patients will be informed verbally by a research nurse.
Patients will be asked for their consent by the research
nurse after a week. If patients can not decide about their
participation at that moment, the research nurse will call
again after another week. Data will be handled confiden-
tially and anonymously. The protocol of the present study
has been approved by the Medical Ethical Committee of
the University Hospital Maastricht (NL16264.068.07/
MEC 07-3-054).
Data management and plan of statistical analysis
Data are entered weekly in a database. Missing data will be
minimized because patients will be visited at home for
filling in the questionnaires and a research nurse will
check if all the questions have been answered. Handling
of missing data will be done according to the guidelines of
the different questionnaires. For data-analysis SPSS 15.0
will be used. All operations will be stored in a SPSS-syntax
file. Interim analysis will be done when each group con-
sists of 50 patients.
Categorical variables will be described as frequencies,
while continuous variables will be tested for normality
and will be presented as mean and standard error of the
mean (SEM) or median, interquartile range and mini-
mum and maximum. Comparison of baseline results
between patients with COPD, CHF and CRF will be done
using parametric and non-parametric statistics and multi-
variate analysis, as appropriate. The presence of co-exist-
ing morbidities will be taken into account. To estimate
longitudinal changes, a mixed effect model for the slopes
can be used. In these analyses, covariates such as age, gen-
der and smoking status can be included as fixed effects,
whereas time can be entered as random effect. Bivariate
relationships between slope changes will be analysed by
using a Pearson's correlation coefficient. Comparison
baseline results between surviving patients with patients
who passed away during the 1-year follow up period will
be done using parametric and non-parametric statistics, as
appropriate. A priori, a two-sided level of significance will
be set at p ≤ 0.05.[47] Additionally, ninety-five percent
confidence intervals will be provided to assist in deter-
mining the clinical significance of the differences of
results between groups of patients.
Discussion
The present study has been designed to assess the self-per-
ceived symptoms, care needs, caregiver burden, prefer-
ences with regard to life-sustaining treatments and
communication about end-of-life care in patients with
end-stage chronic organ failure, in particular COPD, CHF
or CRF. Patients with moderate to severe COPD, CHF or
CRF have been shown to suffer from exercise intolerance,
muscle weakness and abnormal changes in body compo-
sition, irrespective of the degree of primary organ failure.
[48-51] Therefore, it seems reasonable to hypothesize that
patients with end-stage COPD, CHF or CRF have compa-
rable daily symptom burden and care needs.
This study has several strengths and weaknesses, which
will be described below.
Strengths
The present study concerns patients with end-stage
chronic, non-malignant, diseases: COPD, CHF and CRF.
To the present authors' knowledge, this study is the first to
assess symptoms, care-needs, caregiver burden, end-of-life
care treatment preferences and communication needs
from the views of patients with severe to very severe
COPD, patients with end-stage CHF and patients with
end-stage CRF, their loved ones and their treating physi-
cian. Previously have been described the methodological
challenges of research in end-of-life care, like the difficult
task of prospectively identifying the terminally ill.[52] To
date, many studies concerning end-of-life care have a
cross-sectional and retrospective design. Barnes and col-
leagues have previously described the importance of pro-
spective and longitudinal research in chronic
diseases.[53] The prospective and longitudinal design of
this study will allow studying end-of-life care in patients
who are not previously identified as terminally ill. More-
over, the longitudinal and prospective design is less vul-
nerable for measurement error, which is a risk of cross-
sectional or retrospective studies.[54,55] The intended
sample size and the involvement of multiple hospitals
(six general and one academic hospital) will improve the
reliability of the results. The present study will provide
valuable data to an area that has only scarcely been stud-
ied before.
Weaknesses
Patients will be recruited by their treating physician spe-
cialist at the outpatient consultation. The external validity
of the results of the study may be limited due to the exclu-
sion criteria. For example, patients who are not clinically
stable for four weeks will not be included. However, the
exclusion of patients who are not clinically stable has the
major advantage that all patients are clinically stable at
baseline which improves the internal validity of the study.
Additionally, it is possible that participating patients have
other clinical characteristics than non-participating
patients. For example, it is possible that participating
patients will be patients who talk more easily about end-
of-life care than patients who do not want to take part in
the study. Moreover, it is possible that physicians do not
want to ask their terminally ill patients to participate in
the study.BMC Palliative Care 2008, 7:5 http://www.biomedcentral.com/1472-684X/7/5
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Nevertheless, the risk for selection bias will be reduced by
the participation of seven hospitals and about 25 physi-
cians in the recruitment of patients. Additionally, we will
collect some data from a group of non-participating
patients as mentioned before.
A part of the included patients will probably have co-exist-
ing morbidities, not included in the Charlson comorbid-
ity index, like osteoarthritis, which could possibly affect
symptom experience, care needs, health status and car-
egiver burden. Therefore, patients will be asked to report
co-existing morbidities not included in the Charlson
comorbidity index.
The lack of previous results makes it impossible to per-
form power calculations. Therefore a lack of power of this
study may be possible.
Finally, previous authors described the challenges of per-
forming prospective longitudinal research in patients with
end-stage chronic diseases.[44,53] However, the recruit-
ment in the present study will be stimulated by the
involvement of about 25 physicians of 7 hospitals and the
active role of the research nurses in recruitment. The home
visits by a research nurse or researcher will stimulate sus-
taining participation of patients and caregivers. This will
provide patients and caregivers the most convenient set-
ting for data collection.
Clinical consequences
The present study will identify the daily symptoms experi-
enced by patients with severe to very severe COPD, CHF
and CRF. The present study will identify the care needs
which should receive attention in the development of
management programs for patients with severe to very
severe COPD, CHF or CRF. Additionally, the present
study will reveal the end-of-life care treatment preferences
and, if present, the changes in treatment preferences of
patients with end-stage COPD, CHF or CRF, which will
identify which and when treatment preferences should be
discussed with the individual patient and his or her loved
ones. The communication needs and barriers and facilita-
tors of end-of-life care communication which will be
found in this study may give recommendations for
improvement of end-of-life care communication between
patients with end-stage COPD, CHF or CRF, their loved
ones and treating physician. Finally, the present study will
identify the factors affecting caregiver burden, which may
increase the possibilities to influence caregiver burden in
future management programs.
Conclusion
To date, the symptoms, care needs, caregiver burden, end-
of-life care treatment preferences and end-of-life care
communication of patients with very severe COPD, CHF
or CRF have been studied scarcely. The present study will
increase the knowledge about the symptoms, care needs,
caregiver burden, end-of-life care treatment preferences
and communication needs from the views of patients,
their families and their treating physician. This knowledge
is necessary to optimize palliative care for patients with
COPD, CHF or CRF. Here, the study protocol is described
and a preliminary analysis of the possible strengths, weak-
nesses and clinical consequences is outlined.
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